{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:29:16Z","timestamp":1792643356960,"version":"4.5.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:00:00Z","timestamp":1692662400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int Forum Allergy Rhinol"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>This post hoc analysis of the international SINUS\u201024\/\u201052 trials (NCT02912468\/NCT02898454) aimed to assess dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps (CRSwNP) according to different definitions of type 2 inflammatory signature.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Six definitions of type 2 inflammation were used: \u2265150 eosinophils\/\u03bcL or total immunoglobulin E (IgE)\u00a0\u2265100\u00a0IU\/mL with a coexisting type 2 condition; \u2265150 eosinophils\/\u03bcL or total IgE\u00a0\u2265100\u00a0IU\/mL; \u2265150 eosinophils\/\u03bcL; \u2265250 eosinophils\/\u03bcL or total IgE \u2265100\u00a0IU\/mL; coexisting asthma or \u2265300 eosinophils\/\u03bcL; presence of a coexisting type 2 condition. Odds ratios (ORs; dupilumab vs. placebo) for achieving clinically meaningful improvement (\u22651 point) from baseline to week 24 (pooled SINUS\u201024\/\u201052) and week 52 (SINUS\u201052) were calculated for nasal polyp score (NPS; range 0\u20138), nasal congestion\/obstruction score (NC; 0\u22123), and loss of smell score (LoS; 0\u22123).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>At baseline (<jats:italic>n<\/jats:italic>\u00a0=\u00a0724), most patients displayed a type 2 inflammatory signature across definitions (64.2%\u201395.3%). At week 24, ORs for clinically meaningful improvement ranged from 11.9 to 14.9 for NPS across type 2 definitions, 6.5\u20139.6 for NC, and 12.2\u201317.8 for LoS (all <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.0001). OR ranges were similar or greater at week 52: 19.0\u201336.6, 7.6\u201312.1, and 9.2\u201333.5, respectively (all <jats:italic>p<\/jats:italic>\u00a0&lt;\u00a00.0001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Most patients with CRSwNP in the SINUS study had type 2 inflammation. Dupilumab demonstrated robust efficacy across definitions of type 2 inflammation, consistent with its profile as an inhibitor of Interleukin\u20104 and Interleukin\u201013 signaling, key and central drivers of type 2 inflammation in CRSwNP.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Points<\/jats:title><jats:p><jats:list list-type=\"bullet\">\n<jats:list-item><jats:p>This study assessed type 2 inflammation prevalence and dupilumab efficacy in chronic rhinosinusitis with nasal polyps according to algorithm\u2010defined type 2 inflammation<\/jats:p><\/jats:list-item>\n<jats:list-item><jats:p>Dupilumab efficacy was similar across all type 2 definitions<\/jats:p><\/jats:list-item>\n<\/jats:list><\/jats:p><\/jats:sec>","DOI":"10.1002\/alr.23249","type":"journal-article","created":{"date-parts":[[2023,8,7]],"date-time":"2023-08-07T08:46:29Z","timestamp":1691397989000},"page":"668-678","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS\u201024 and SINUS\u201052"],"prefix":"10.1002","volume":"14","author":[{"given":"Claus","family":"Bachert","sequence":"first","affiliation":[{"name":"University Hospital of M\u00fcnster  M\u00fcnster Germany"},{"name":"Sun Yat\u2010sen University The First Affiliated Hospital  Guangzhou China"},{"name":"Karolinska Hospital Stockholm University  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asif H.","family":"Khan","sequence":"additional","affiliation":[{"name":"Sanofi  Chilly Mazarin France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stella E.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Otolaryngology \u2013 Head and Neck Surgery Brigham and Women's Hospital Harvard Medical School  Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3993-1569","authenticated-orcid":false,"given":"Claire","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Guy's and St Thomas\u2019 Hospitals  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anju T.","family":"Peters","sequence":"additional","affiliation":[{"name":"Allergy\u2010Immunology Division and the Sinus and Allergy Center Feinberg School of Medicine Northwestern University  Chicago Illinois USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytske","family":"Fokkens","sequence":"additional","affiliation":[{"name":"Academic Medical Center  Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Praestgaard","sequence":"additional","affiliation":[{"name":"Sanofi  Cambridge Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amr","family":"Radwan","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Uxbridge UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Nash","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juby A.","family":"Jacob\u2010Nara","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamo","family":"Deniz","sequence":"additional","affiliation":[{"name":"Regeneron Pharmaceuticals Inc.  Tarrytown New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Sanofi  Bridgewater New Jersey USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,8,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.12.1324"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2019.05.009"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31881-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.12.324"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.4193\/Rhin20.401"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.013"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/all.14425"},{"key":"e_1_2_8_9_1","unstructured":"Global Initiative for Asthma.Global strategy for asthma management and prevention 2021. Accessed February 18 2022.https:\/\/ginasthma.org\/wp-content\/uploads\/2021\/05\/GINA\u2010Main\u2010Report\u20102021\u2010V2\u2010WMS.pdf"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/lary.29888"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-4486.2009.01995.x"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.02.002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaip.2021.09.037"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.09.009"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13601-020-00332-z"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.06.063"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11102684"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12091526"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00405-022-07679-y"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00085-2022"}],"container-title":["International Forum of Allergy &amp; Rhinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/alr.23249","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,11]],"date-time":"2024-03-11T03:18:14Z","timestamp":1710127094000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/alr.23249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,22]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["10.1002\/alr.23249"],"URL":"https:\/\/doi.org\/10.1002\/alr.23249","archive":["Portico"],"relation":{},"ISSN":["2042-6976","2042-6984"],"issn-type":[{"value":"2042-6976","type":"print"},{"value":"2042-6984","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,22]]},"assertion":[{"value":"2023-01-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-07-31","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}